CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that the United States Patent and Trademark Office granted to AVEO U.S. Patent No. 7,556,796. This patent provides robust protection for AVEO’s “directed complementation” technology, which significantly enhances the flexibility and efficiency of AVEO’s research and development programs and supports the company’s proprietary, integrated cancer biology platform.
